SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA - PubMed (original) (raw)

. 2019 Feb 1;34(2):208-230.

doi: 10.1093/ndt/gfy407.

Charles J Ferro 2, Enrique Morales 3, Alberto Ortiz 4, Jolanta Malyszko 5, Radovan Hojs 6, Khaled Khazim 7, Robert Ekart 6, Jose Valdivielso 8, Denis Fouque 9, Gérard M London 10, Ziad Massy 11, Petro Ruggenenti 12, Esteban Porrini 13, Andrzej Wiecek 14, Carmine Zoccali 15, Francesca Mallamaci 15, Mads Hornum 16

Affiliations

• PMID: 30753708
• DOI: 10.1093/ndt/gfy407

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

Pantelis Sarafidis et al. Nephrol Dial Transplant. 2019.

Erratum in

• Erratum.
  Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M. Sarafidis P, et al. Nephrol Dial Transplant. 2020 Aug 1;35(8):1452. doi: 10.1093/ndt/gfz047. Nephrol Dial Transplant. 2020. PMID: 30820538 No abstract available.
• SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
  Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M. Sarafidis P, et al. Nephrol Dial Transplant. 2020 Oct 1;35(10):1825. doi: 10.1093/ndt/gfz137. Nephrol Dial Transplant. 2020. PMID: 31397476 No abstract available.

Abstract

Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. Currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM have emerged, including inhibitors of renal sodium-glucose co-transporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. Apart from reducing glycaemia, these classes were reported to have other beneficial effects for the cardiovascular and renal systems, such as weight loss and blood pressure reduction. Most importantly, in contrast to all previous studies with anti-diabetic agents, a series of recent randomized, placebo-controlled outcome trials showed that SGLT-2 inhibitors and GLP-1 receptor agonists are able to reduce cardiovascular events and all-cause mortality, as well as progression of renal disease, in patients with type 2 DM. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of SGLT-2 inhibitors and GLP-1 analogues, analyses the potential mechanisms involved in these actions and discusses their place in the treatment of patients with CKD and DM.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information